Company intelligence / Profile preview

iQure Pharma Inc.

Princeton, New Jersey, United Statesiqurepharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

iQure Pharma's lead asset iQ-007 is a first-in-class EAAT2 Positive Allosteric Modulator (PAM) designed to address toxic levels of glutamate in the synaptic cleft. The company secured $4M funding in January 2025 to progress with a Phase 1 clinical trial for iQ-007. Previously, in October 2023, they raised $1.2M to progress with IND-enabling pivotal tox studies for iQ-007. The compound has successfully completed the NIH ETSP epilepsy screening program.[4][5]

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

iQ-007

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on iQure Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iQure Pharma Inc..

Explore the full profile